Â鶹´«Ã½ÊÓƵÍøÕ¾

XClose

Â鶹´«Ã½ÊÓƵÍøÕ¾ Therapeutic Innovation Networks

Home
Menu

Accelerating Translation

Collaborations maximise the translation of Â鶹´«Ã½ÊÓƵÍøվ’s biomedical science

The TIN concept has been piloted with the Cell, Gene & Regenerative Medicine (CG&RM) community which has benefited from having a dedicated coordinator to galvanise and support the community. The impact of the initial work performed by the CG&RM TIN has been as a catalyst across Â鶹´«Ã½ÊÓƵÍøÕ¾ and our partner hospitals, linking up bioengineering with SLMS/BRC academics and clinicians to solve challenges in manufacturing and clinical delivery.

In addition it has raised the profile internally to recognise the collective international standing of our researchers in this field (Â鶹´«Ã½ÊÓƵÍøÕ¾ and our partner NHS Trusts participate in 34 out of 58 of all open UK advanced therapy trials i.e. 59%), competing with US institutions such as Harvard (55 trials), U.Penn (48 trials) as well as countries in Europe, France (47 trials), Germany (42 trials) and Spain (38 trials).ÌýThe early focus of the coordinator was to map the Â鶹´«Ã½ÊÓƵÍøÕ¾ and partner hospital CG&RM landscape in terms of centres of excellence in research and clinical activity, physical facilities, funding, portfolio analysis, etc. The information gathered to date contributed to the development of a cross cutting themes in CG&RM that is common to all three Â鶹´«Ã½ÊÓƵÍøÕ¾ NIHR BRCs (Â鶹´«Ã½ÊÓƵÍøÕ¾H, GOSH and Moorfields).Ìý

The community has now had several events organised, linking engineers with clinicians, showcasing individual projects as well as some of the commercial successes highlighting the support available through Â鶹´«Ã½ÊÓƵÍøÕ¾B, TRO, CTU etc. Ìý

We now wish to maintain this level of support and expand to other therapeutic modalities.

ATMP pan-London analysis

Cell, Gene & RegMed TIN led pan-London analysis (2017) of future demand for GMP manufacturing.